Aesthetic device company Alma has announced that it is the exclusive UK distributor for South Korean biotechnology company ExoCoBio.
The partnership aims to expand Alma’s UK portfolio beyond energy-based technologies and injectables to include regenerative aesthetic solutions powered by exosome-based treatments. By integrating ExoCoBio’s technology into its offering, Alma aims to help aesthetic clinics enhance treatment outcomes, support faster recovery and deliver a more comprehensive patient experience across the UK and Ireland.
Adam Bashier, Alma UK&I managing director, commented, “At Alma, we are committed to continuously evolving our offering to meet the changing needs of modern aesthetic practice. This collaboration with ExoCoBio represents a natural progression towards a more complete treatment ecosystem to deliver better outcomes for both practitioners and patients.”